Molecular Mechanisms of l-DOPA-Induced Dyskinesia
作者： M.A. Cenci
DOI: 10.1016/B978-0-12-802206-1.00043-X
关键词: Glutamatergic 、 Biology 、 Postsynaptic potential 、 Striatum 、 Dopamine 、 Abnormal involuntary movement 、 Parkinson's disease 、 Endocrinology 、 Glutamate receptor 、 Dyskinesia 、 Neuroscience 、 Internal medicine
摘要: The dopamine (DA) precursor, 3,4-dihydroxyphenyl-L-alanine (L-DOPA), is the most effective treatment for Parkinson's disease (PD), but causes dyskinesias (abnormal involuntary movements) in vast majority of patients. There a wide consensus that L-DOPA-induced dyskinesia (LID) depends on both pre- and postsynaptic disturbances nigrostriatal DA transmission. Presynaptically, LID associated with abnormal release defective clearance, which converge to cause large swings brain levels concomitant medication. Postsynaptically, dysregulation intracellular signaling gene expression downstream D1 receptor. These phenomena are particularly well studied striatum thus main topic this chapter. In addition, chapter reviews studies have revealed associations between different types abnormalities glutamatergic GABAergic transmission within cortico-basal ganglia circuits. (Less)
sci-hub.se 参考文章(190)
H. Iderberg, A.C. McCreary, M.A. Varney, M.A. Cenci, A. Newman-Tancredi, Activity of serotonin 5-HT1A receptor 'biased agonists' in rat models of Parkinson's disease and l-DOPA-induced dyskinesia. Neuropharmacology. ,vol. 93, pp. 52- 67 ,(2015) , 10.1016/J.NEUROPHARM.2015.01.012
Agnès Nadjar, Charles R. Gerfen, Erwan Bezard, Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease? Progress in Neurobiology. ,vol. 87, pp. 1- 9 ,(2009) , 10.1016/J.PNEUROBIO.2008.09.013
J. E. Westin, M. Andersson, M. Lundblad, M. A. Cenci, Persistent changes in striatal gene expression induced by long-terml-DOPA treatment in a rat model of Parkinson's disease European Journal of Neuroscience. ,vol. 14, pp. 1171- 1176 ,(2001) , 10.1046/J.0953-816X.2001.01743.X
C. A. Ingham, S. H. Hood, B. van Maldegem, A. Weenink, G. W. Arbuthnott, Morphological changes in the rat neostriatum after unilateral 6-hydroxydopamine injections into the nigrostriatal pathway. Experimental Brain Research. ,vol. 93, pp. 17- 27 ,(1993) , 10.1007/BF00227776
V. Bagetta, C. Sgobio, V. Pendolino, G. Del Papa, A. Tozzi, V. Ghiglieri, C. Giampa, E. Zianni, F. Gardoni, P. Calabresi, B. Picconi, Rebalance of Striatal NMDA/AMPA Receptor Ratio Underlies the Reduced Emergence of Dyskinesia During D2-Like Dopamine Agonist Treatment in Experimental Parkinson's Disease The Journal of Neuroscience. ,vol. 32, pp. 17921- 17931 ,(2012) , 10.1523/JNEUROSCI.2664-12.2012
Nicholas M. Barnes, Trevor Sharp, A review of central 5-HT receptors and their function Neuropharmacology. ,vol. 38, pp. 1083- 1152 ,(1999) , 10.1016/S0028-3908(99)00010-6
M. Heiman, A. Heilbut, V. Francardo, R. Kulicke, R. J. Fenster, E. D. Kolaczyk, J. P. Mesirov, D. J. Surmeier, M. A. Cenci, P. Greengard, Molecular adaptations of striatal spiny projection neurons during levodopa-induced dyskinesia Proceedings of the National Academy of Sciences of the United States of America. ,vol. 111, pp. 4578- 4583 ,(2014) , 10.1073/PNAS.1401819111
B.C Tel, B.-Y Zeng, C Cannizzaro, R.K.B Pearce, S Rose, P Jenner, Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets. Neuroscience. ,vol. 115, pp. 1047- 1058 ,(2002) , 10.1016/S0306-4522(02)00535-3
C.A. Ingham, S.H. Hood, G.W. Arbuthnott, Spine density on neostriatal neurones changes with 6-hydroxydopamine lesions and with age Brain Research. ,vol. 503, pp. 334- 338 ,(1989) , 10.1016/0006-8993(89)91686-7
Rochdi Bouhelal, Larbi Smounya, Joël Bockaert, 5-HT1B receptors are negatively coupled with adenylate cyclase in rat substantia nigra. European Journal of Pharmacology. ,vol. 151, pp. 189- 196 ,(1988) , 10.1016/0014-2999(88)90799-6